ClinicalTrials.gg
TerminatedNCT00174291Updated Dec 4, 2012Results posted

Prevention of Growth Retardation by Early Treatment With Growth Hormone (GH) in Children With CJA Treated by Corticosteroid Therapy

A Phase 3 interventional study of Somatropin in Endocrine System Diseases, sponsored by Pfizer. Terminated at 1 site in France. Open to participants aged 4 Years to 14 Years. Per ClinicalTrials.gov, last updated 2012-12-04.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Why this study was terminated
See termination reason in detailed description.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
21
Allocation
Non-randomized
Ages
4 Years to 14 Years
Sex
All
01

Study summary

  • To evaluate the effect of increasing the growth hormone dose on the statural response
  • To assess the value of early treatment during the course of arthritic disease by comparing the height acquired in the medium term by children in the two groups: treated from the start, or 1 year to 15 months after the diagnosis of CJA, or treated for 4 years after the diagnosis
Read the detailed description

This trial terminated on 10-Jun-2011 due to prolonged issues with drug accountability and data collection discrepancies. The decision to terminate was not based on any safety concerns.

02

Conditions studied

  • Endocrine System Diseases
03

In context

Endocrine System Diseases

322 studies on the registry are indexed under Endocrine System Diseases; 51 are open to participants now.

This study's enrollment of 21 is below the median of 69 across 221 interventional studies indexed under Endocrine System Diseases.

Browse Endocrine System Diseases studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 146 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • This study will be proposed to all patients previously included in study CTN 97-8129-016

Exclusion criteria

Exclusion Criteria:

  • Discontinuation of therapy for more than a year during study CTN 97-8129-016
  • Patients withdrawing from the study prematurely
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Somatropin

    Drug: Somatropin

Interventions

  • Liquid, daily to final height Maximum Dosage: 50 µg/kg/day

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Annual Rate of Growth Standard Deviation Score (SDS) at Year 3

    Annual rate of growth SDS was obtained by measuring the annual growth rate, subtracting chronological age- and gender-appropriate mean annual growth rate and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.

    Time frame: Baseline, Year 3

  2. Change From Baseline in Annual Rate of Growth Standard Deviation Score (SDS) at Final Height

    Annual rate of growth SDS was obtained by measuring the annual growth rate, subtracting chronological age- and gender-appropriate mean annual growth rate and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.

    Time frame: Baseline, final height (assessed up to Year 9.5)

  3. Change From Baseline in Height Standard Deviation Score (SDS) at Year 3

    Height was measured using a wall mounted device (example, Harpenden stadiometer). Height SDS was obtained by measuring the height, subtracting chronological age- and gender-appropriate mean height and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.

    Time frame: Baseline, Year 3

  4. Change From Baseline in Height Standard Deviation Score (SDS) at Final Height

    Height was measured using a wall mounted device (example, Harpenden stadiometer). Height SDS was obtained by measuring the height, subtracting chronological age- and gender-appropriate mean height and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.

    Time frame: Baseline, final height (assessed up to Year 9.5)

  5. Change From Baseline in Predicted Height Standard Deviation Score (SDS) at Year 3

    Predicted height was calculated according to Greulich and Pyle using Bayley Pinneau method. Predicted height SDS was obtained by calculating the predicted height, subtracting chronological age- and gender-appropriate mean predicted height and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.

    Time frame: Baseline, Year 3

  6. Change From Baseline in Predicted Height Standard Deviation Score (SDS) at Final Height

    Predicted height was calculated according to Greulich and Pyle using Bayley Pinneau method. Predicted height SDS was obtained by calculating the predicted height, subtracting chronological age- and gender-appropriate mean predicted height and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.

    Time frame: Baseline, final height (assessed up to Year 9.5)

Secondary outcomes

  1. Change From Baseline in Insulin-like Growth Factor-1 (IGF-1) Concentration at Year 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5 and 9

    Time frame: Baseline, Year 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9

  2. Change From Baseline in Insulin-like Growth Factor Binding Protein 3 (IGFBP3) Concentration at Year 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5 and 9

    Time frame: Baseline, Year 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9

  3. Change From Baseline in Lean Mass and Fat Mass at Year 1, 2, 3, 4, 5, 6, 7, 8 and 9

    Lean mass and fat mass: measurements of body composition assessed using Dual Energy X-ray Absorptiometry (DEXA) scan.

    Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9

  4. Change From Baseline in Bone Mineralization at Year 1, 2, 3, 4, 5, 6, 7, 8 and 9

    Bone mineralization, an estimate of the amount of mineral (such as calcium) in the bone, was assessed using DEXA scan.

    Time frame: Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9

  5. Change From Baseline in Weight Standard Deviation Score (SDS) at Year 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5 and 9

    Body weight was measured using a balance scale. Weight SDS was obtained by measuring the weight, subtracting age- and gender- appropriate mean weight and dividing the result by standard deviation of that mean (as obtained from age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.

    Time frame: Baseline, Year 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9

  6. Change From Baseline in Corticosteroid Dose at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5 and 9

    Time frame: Baseline, Year 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9

07

Results

Posted Dec 4, 2012
Limitations and caveats
Data for bone mineral density (BMD), bone mineral content (BMC) and IGFBP3 were not analyzed because of change in planned analysis after the study was prematurely terminated due to Good Clinical Practice (GCP) non-compliance issues.

Participant flow

Participants included in previous study CTN 97-8129-016 were eligible for this study.

Participant flow — Overall Study
MilestoneSomatropin (With Previous Somatropin Exposure)Somatropin (Without Previous Somatropin Exposure)
Started1110
Completed64
Not completed56
Withdrew: Lost to follow-up11
Withdrew: Protocol violation02
Withdrew: Study terminated by sponsor10
Withdrew: Withdrawal by subject33

Outcome measures

PrimaryChange From Baseline in Annual Rate of Growth Standard Deviation Score (SDS) at Year 3

Annual rate of growth SDS was obtained by measuring the annual growth rate, subtracting chronological age- and gender-appropriate mean annual growth rate and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.

Time frame:
Baseline, Year 3
Reported as:
Median · SDS
Change From Baseline in Annual Rate of Growth Standard Deviation Score (SDS) at Year 3
SDSSomatropin (With Previous Somatropin Exposure)Somatropin (Without Previous Somatropin Exposure)
Baseline-0.21 (-3.0 to 4.5)-2.96 (-6.4 to 1.5)
Change at Year 31.34 (-3.6 to 6.2)3.52 (-5.1 to 11.2)
PrimaryChange From Baseline in Annual Rate of Growth Standard Deviation Score (SDS) at Final Height

Annual rate of growth SDS was obtained by measuring the annual growth rate, subtracting chronological age- and gender-appropriate mean annual growth rate and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.

Time frame:
Baseline, final height (assessed up to Year 9.5)

No measurements were reported for this outcome.

PrimaryChange From Baseline in Height Standard Deviation Score (SDS) at Year 3

Height was measured using a wall mounted device (example, Harpenden stadiometer). Height SDS was obtained by measuring the height, subtracting chronological age- and gender-appropriate mean height and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.

Time frame:
Baseline, Year 3
Reported as:
Median · SDS
Change From Baseline in Height Standard Deviation Score (SDS) at Year 3
SDSSomatropin (With Previous Somatropin Exposure)Somatropin (Without Previous Somatropin Exposure)
Baseline-0.61 (-3.7 to 1.4)-2.34 (-4.8 to -1.4)
Change at Year 30.73 (-2.4 to 2.6)1.21 (-0.7 to 2.4)
PrimaryChange From Baseline in Height Standard Deviation Score (SDS) at Final Height

Height was measured using a wall mounted device (example, Harpenden stadiometer). Height SDS was obtained by measuring the height, subtracting chronological age- and gender-appropriate mean height and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.

Time frame:
Baseline, final height (assessed up to Year 9.5)
Reported as:
Median · SDS
Change From Baseline in Height Standard Deviation Score (SDS) at Final Height
SDSSomatropin (With Previous Somatropin Exposure)Somatropin (Without Previous Somatropin Exposure)
Baseline0.96 (-3.7 to 2.3)-0.94 (-1.4 to -0.5)
Change at Final Height-0.43 (-0.8 to 0.5)0.08 (-0.7 to 0.9)
PrimaryChange From Baseline in Predicted Height Standard Deviation Score (SDS) at Year 3

Predicted height was calculated according to Greulich and Pyle using Bayley Pinneau method. Predicted height SDS was obtained by calculating the predicted height, subtracting chronological age- and gender-appropriate mean predicted height and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.

Time frame:
Baseline, Year 3
Reported as:
Median · SDS
Change From Baseline in Predicted Height Standard Deviation Score (SDS) at Year 3
SDSSomatropin (With Previous Somatropin Exposure)Somatropin (Without Previous Somatropin Exposure)
Baseline-0.76 (-1.8 to 0.7)-2.43 (-2.6 to -1.6)
Change at Year 30.68 (-2.6 to 2.0)1.63 (0.1 to 2.3)
PrimaryChange From Baseline in Predicted Height Standard Deviation Score (SDS) at Final Height

Predicted height was calculated according to Greulich and Pyle using Bayley Pinneau method. Predicted height SDS was obtained by calculating the predicted height, subtracting chronological age- and gender-appropriate mean predicted height and dividing the result by standard deviation of that mean (as obtained from chronological age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.

Time frame:
Baseline, final height (assessed up to Year 9.5)
Reported as:
Median · SDS
Change From Baseline in Predicted Height Standard Deviation Score (SDS) at Final Height
SDSSomatropin (With Previous Somatropin Exposure)Somatropin (Without Previous Somatropin Exposure)
Baseline-0.84 (-1.8 to 0.1)-1.74 (-2.4 to -1.1)
Change at Final Height-0.67 (-2.4 to 1.0)0.71 (0.1 to 1.3)
SecondaryChange From Baseline in Insulin-like Growth Factor-1 (IGF-1) Concentration at Year 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5 and 9
Time frame:
Baseline, Year 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9
Reported as:
Median · milligram per deciliter (mg/dL)
Change From Baseline in Insulin-like Growth Factor-1 (IGF-1) Concentration at Year 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5 and 9
milligram per deciliter (mg/dL)Somatropin (With Previous Somatropin Exposure)Somatropin (Without Previous Somatropin Exposure)
Baseline (n = 11, 10)0.0361 (0.0181 to 0.0868)0.0165 (0.0075 to 0.0517)
Change at Year 0.5 (n = 9, 10)0.0017 (-0.0256 to 0.0681)0.0255 (-0.0145 to 0.0390)
Change at Year 1 (n = 11, 10)0.0093 (-0.0358 to 0.0488)0.0329 (-0.0061 to 0.0531)
Change at Year 1.5 (n = 11, 9)0.0066 (-0.0194 to 0.0599)0.0406 (-0.0035 to 0.0754)
Change at Year 2 (n = 10, 9)0.0221 (-0.0292 to 0.0534)0.0223 (0.0055 to 0.0673)
Change at Year 2.5 (n = 8, 8)0.0201 (-0.0237 to 0.0470)0.0366 (-0.0109 to 0.0558)
Change at Year 3 (n = 7, 9)0.0130 (-0.0049 to 0.0648)0.0445 (-0.0060 to 0.0557)
Change at Year 3.5 (n = 7, 7)0.0100 (-0.0022 to 0.0436)0.0396 (0.0014 to 0.0707)
Change at Year 4 (n = 6, 7)0.0212 (-0.0014 to 0.0485)0.0453 (0.0175 to 0.0646)
Change at Year 4.5 (n = 5, 6)0.0142 (0.0042 to 0.0303)0.0431 (0.0080 to 0.1233)
Change at Year 5 (n = 5, 7)0.0236 (0.0164 to 0.0530)0.0369 (0.0258 to 0.0902)
Change at Year 5.5 (n = 4, 5)0.0186 (0.0119 to 0.0356)0.0448 (0.0258 to 0.0965)
Change at Year 6 (n = 4, 5)0.0256 (0.0000 to 0.0434)0.0454 (0.0155 to 0.0718)
Change at Year 6.5 (n = 2, 5)0.0195 (0.0125 to 0.0264)0.0593 (0.0512 to 0.0766)
Change at Year 7 (n = 1, 5)0.0254 (0.0254 to 0.0254)0.0424 (0.0393 to 0.0766)
Change at Year 7.5 (n = 0, 3)NA (NA to NA)0.0529 (0.0527 to 0.0599)
Change at Year 8 (n = 0, 2)NA (NA to NA)0.0576 (0.0468 to 0.0683)
Change at Year 8.5 (n = 0, 1)NA (NA to NA)0.0280 (0.0280 to 0.0280)
Change at Year 9 (n = 2, 1)0.0363 (0.0159 to 0.0567)0.0403 (0.0403 to 0.0403)
SecondaryChange From Baseline in Insulin-like Growth Factor Binding Protein 3 (IGFBP3) Concentration at Year 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5 and 9
Time frame:
Baseline, Year 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9

No measurements were reported for this outcome.

SecondaryChange From Baseline in Lean Mass and Fat Mass at Year 1, 2, 3, 4, 5, 6, 7, 8 and 9

Lean mass and fat mass: measurements of body composition assessed using Dual Energy X-ray Absorptiometry (DEXA) scan.

Time frame:
Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9

No measurements were reported for this outcome.

SecondaryChange From Baseline in Bone Mineralization at Year 1, 2, 3, 4, 5, 6, 7, 8 and 9

Bone mineralization, an estimate of the amount of mineral (such as calcium) in the bone, was assessed using DEXA scan.

Time frame:
Baseline, Year 1, 2, 3, 4, 5, 6, 7, 8, 9
Reported as:
Median · grams
Change From Baseline in Bone Mineralization at Year 1, 2, 3, 4, 5, 6, 7, 8 and 9
gramsSomatropin (With Previous Somatropin Exposure)Somatropin (Without Previous Somatropin Exposure)
Baseline (n = 11, 10)643.00 (454.0 to 998.0)565.40 (136.0 to 1305.0)
Change at Year 1 (n = 11, 10)118.40 (-792.7 to 459.6)104.67 (9.0 to 340.0)
Change at Year 2 (n = 10, 9)231.30 (-47.5 to 774.4)272.70 (63.0 to 590.0)
Change at Year 3 (n = 7, 8)403.80 (25.0 to 862.5)375.27 (106.0 to 1084.9)
Change at Year 4 (n = 4, 3)903.20 (277.1 to 1448.1)518.70 (450.8 to 1047.9)
Change at Year 5 (n = 4, 7)938.30 (591.8 to 1787.6)829.00 (421.7 to 1245.8)
Change at Year 6 (n = 4, 5)998.05 (371.4 to 1984.2)818.40 (112.5 to 1105.5)
Change at Year 7 (n = 1, 5)1408.50 (1408.5 to 1408.5)1206.10 (739.6 to 1437.3)
Change at Year 8 (n = 0, 2)NA (NA to NA)1376.05 (1351.7 to 1400.4)
Change at Year 9 (n = 2, 1)1210.15 (898.6 to 1521.7)1376.30 (1376.3 to 1376.3)
SecondaryChange From Baseline in Weight Standard Deviation Score (SDS) at Year 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5 and 9

Body weight was measured using a balance scale. Weight SDS was obtained by measuring the weight, subtracting age- and gender- appropriate mean weight and dividing the result by standard deviation of that mean (as obtained from age- and gender-specific population reference data). SDS indicated how many standard deviations higher (in case of positive SDS) or lower (in case of negative SDS) participant's value was relative to the mean of the reference population.

Time frame:
Baseline, Year 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9
Reported as:
Median · SDS
Change From Baseline in Weight Standard Deviation Score (SDS) at Year 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5 and 9
SDSSomatropin (With Previous Somatropin Exposure)Somatropin (Without Previous Somatropin Exposure)
Baseline (n = 11, 10)0.04 (-5.4 to 5.0)-2.06 (-4.0 to 2.6)
Change at Year 0.5 (n = 9, 10)0.06 (-0.8 to 1.2)0.25 (-0.7 to 0.4)
Change at Year 1 (n = 11, 10)0.25 (-1.1 to 0.9)0.31 (-0.1 to 1.5)
Change at Year 1.5 (n = 11, 9)0.34 (-1.6 to 2.3)0.62 (-0.3 to 2.3)
Change at Year 2 (n = 10, 9)0.46 (-1.1 to 2.2)1.23 (-0.2 to 2.7)
Change at Year 2.5 (n = 8, 8)0.77 (-1.1 to 2.6)1.51 (-0.9 to 3.2)
Change at Year 3 (n = 7, 9)0.61 (-1.2 to 2.7)1.48 (-1.9 to 3.7)
Change at Year 3.5 (n = 7, 7)0.78 (-1.3 to 3.0)1.56 (-1.9 to 3.7)
Change at Year 4 (n = 6, 7)0.58 (-1.0 to 2.4)1.96 (-2.3 to 3.8)
Change at Year 4.5 (n = 5, 6)1.46 (-0.4 to 2.7)1.78 (-2.7 to 4.1)
Change at Year 5 (n = 5, 7)2.06 (0.1 to 2.8)2.08 (-3.0 to 3.9)
Change at Year 5.5 (n = 3, 5)2.10 (1.7 to 2.6)3.25 (1.0 to 3.8)
Change at Year 6 (n = 3, 5)1.89 (1.8 to 2.2)2.95 (1.2 to 4.4)
Change at Year 6.5 (n = 2, 5)2.03 (1.9 to 2.2)3.30 (0.8 to 5.0)
Change at Year 7 (n = 1, 5)1.7 (1.7 to 1.7)2.91 (0.2 to 5.2)
Change at Year 7.5 (n = 0, 3)NA (NA to NA)1.49 (0.3 to 3.1)
Change at Year 8 (n = 0, 2)NA (NA to NA)1.06 (0.5 to 1.6)
Change at Year 8.5 (n = 0, 1)NA (NA to NA)0.7 (0.7 to 0.7)
Change at Year 9 (n = 1, 1)2.0 (2.0 to 2.0)1.4 (1.4 to 1.4)
SecondaryChange From Baseline in Corticosteroid Dose at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5 and 9
Time frame:
Baseline, Year 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9
Reported as:
Median · mg
Change From Baseline in Corticosteroid Dose at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5 and 9
mgSomatropin (With Previous Somatropin Exposure)Somatropin (Without Previous Somatropin Exposure)
Baseline (n = 11, 10)7.50 (1.0 to 40.0)4.75 (2.0 to 13.5)
Change at Year 0.5 (n = 9, 10)0.00 (-11.0 to 0.0)0.00 (-2.5 to 4.8)
Change at Year 1 (n = 11, 9)0.00 (-15.0 to 20.3)-0.67 (-8.5 to 36.0)
Change at Year 1.5 (n = 11, 8)0.00 (-17.0 to 7.5)0.50 (-5.0 to 8.8)
Change at Year 2 (n = 10, 8)0.00 (-19.0 to 10.6)-0.50 (-6.3 to 11.9)
Change at Year 2.5 (n = 8, 7)0.04 (-28.0 to 7.5)1.83 (-7.8 to 11.9)
Change at Year 3 (n = 7, 7)0.00 (-34.2 to 1.0)1.75 (-9.5 to 19.4)
Change at Year 3.5 (n = 7, 6)-0.75 (-36.0 to 2.9)1.83 (-10.3 to 12.5)
Change at Year 4 (n = 6, 7)-1.88 (-4.5 to 0.0)0.25 (-10.0 to 9.7)
Change at Year 4.5 (n = 5, 6)-3.40 (-10.0 to 0.0)0.23 (-9.0 to 215.4)
Change at Year 5 (n = 5, 7)-3.50 (-10.0 to -0.6)-2.00 (-9.5 to 15.0)
Change at Year 5.5 (n = 4, 5)-1.83 (-4.5 to 486.5)0.25 (-9.5 to 18.3)
Change at Year 6 (n = 4, 5)-1.83 (-5.5 to 9.0)-1.00 (-11.0 to 10.6)
Change at Year 6.5 (n = 2, 5)-2.46 (-3.7 to -1.3)-1.00 (-11.0 to 3.0)
Change at Year 7 (n = 1, 5)-2.50 (-2.5 to -2.5)-1.00 (-11.0 to 2.0)
Change at Year 7.5 (n = 0, 3)NA (NA to NA)-7.00 (-12.0 to 0.5)
Change at Year 8 (n = 0, 2)NA (NA to NA)-3.25 (-7.0 to 5.0)
Change at Year 8.5 (n = 0, 1)NA (NA to NA)0.50 (0.5 to 0.5)
Change at Year 9 (n = 2, 1)-3.00 (-3.5 to -2.5)-7.00 (-7.0 to -7.0)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Somatropin (With Previous Somatropin Exposure)—6/11 (54.5%)11/11 (100%)
Somatropin (Without Previous Somatropin Exposure)—2/10 (20%)9/10 (90%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventSomatropin (With Previous Somatropin Exposure)Somatropin (Without Previous Somatropin Exposure)
Juvenile arthritisMusculoskeletal and connective tissue disorders2/110/10
LymphadenitisBlood and lymphatic system disorders0/111/10
PyrexiaGeneral disorders1/111/10
Lung infectionInfections and infestations0/111/10
SinusitisInfections and infestations0/111/10
Pain in extremityMusculoskeletal and connective tissue disorders0/111/10
Melanocytic naevusNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/111/10
HeadacheNervous system disorders0/111/10
Nephrotic syndromeRenal and urinary disorders0/111/10
Renal failure acuteRenal and urinary disorders0/111/10
Most frequent other events
Showing 10 of 99
Most frequent other events
EventSomatropin (With Previous Somatropin Exposure)Somatropin (Without Previous Somatropin Exposure)
Insulin-like growth factor increasedInvestigations8/116/10
Insulin resistanceMetabolism and nutrition disorders6/115/10
Glucose tolerance impairedMetabolism and nutrition disorders5/110/10
Juvenile arthritisMusculoskeletal and connective tissue disorders4/114/10
BronchitisInfections and infestations1/113/10
GastritisGastrointestinal disorders0/112/10
FatigueGeneral disorders0/112/10
Ear infectionInfections and infestations1/112/10
Herpes zosterInfections and infestations0/112/10
Nail candidaInfections and infestations0/112/10

Baseline characteristics

Age Continuous
Age Continuous(years)Somatropin (With Previous Somatropin Exposure)Somatropin (Without Previous Somatropin Exposure)Total
Mean8.3 ± 2.68.5 ± 3.38.4 ± 2.9
Sex: Female, Male
Sex: Female, Male(Participants)Somatropin (With Previous Somatropin Exposure)Somatropin (Without Previous Somatropin Exposure)Total
Female6410
Male5611
08

Study locations

1 site
  • Pfizer Investigational Site
    Paris, 75019, France
09

References and documents

Publications

  • David H, Aupiais C, Louveau B, Quartier P, Jacqz-Aigrain E, Carel JC, Simon D. Growth Outcomes After GH Therapy of Patients Given Long-Term Corticosteroids for Juvenile Idiopathic Arthritis. J Clin Endocrinol Metab. 2017 Dec 1;102(12):4578-4587. doi: 10.1210/jc.2017-01455. PubMed 29029101 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2002, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2012, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2005
First posted
Sep 15, 2005
Start
Mar 2002
Primary completionActual
Oct 2011
CompletionActual
Oct 2011
Results first posted
Dec 4, 2012
Last update
Dec 4, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00174291
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 15, 2005
Start date
Mar 2002
Primary completion
Oct 2011
Completion
Oct 2011
Results posted
Dec 4, 2012
Last update
Dec 4, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion